Bio-Rad Intends to Propose Three New Independent Directors
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/3/2026
- Wall Street rallies, Dow closes at record on Iran talks optimism
- Fed's Williams says rate hikes possible if inflation persists
- Citi says buy these 3 chip stocks on pullback
- Microsoft joins, Broadcom exits Goldman's top-stocks list
- Deutsche Bank raises S&P 500 earnings estimates on the back of the solid Q2 beats
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
Bio-Rad Labs (BIO) PT Raised to $250 at Jefferies; Sees Path to $300
March 14, 2017 6:37 AM EDTJefferies raised its price target on Bio-Rad Labs (NYSE: BIO) to $250.00 (from $225.00) while maintaining a Buy rating. The analyst also sees a path to $300 share.
Analyst Brandon Couillard commented, "Time to forget everything you thought you knew about BIO -- as two separate... More
